An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy

NCT02068365 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepaititis B

Interventions

DRUG: Pegyinterferon-alfa-2a

Sponsor

Chinese University of Hong Kong